OS Therapies Incorporated (OSTX) News
Track canonical SquawkNews coverage tagged to OSTX, OS Therapies Incorporated. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
OS Therapies Expects Phase 3 Study For The OST-HER2 Metastatic Osteosarcoma Program To Begin Near End Of Q3 2026
OS Therapies, Inc. (NYSE: OSTX ) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provides a third quarter 2026 corporate outlook. The outlook focuses on up
FX | Jul 06, 2026, 01:10 PM UTC
L
OS Therapies Third Quarter 2026 Corporate Outlook
Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market access
REGULATION | Jul 06, 2026, 01:01 PM UTC
H
OS Therapies shares are trading lower. The company requested a Type B Meeting to follow up on FDA guidance for its OST‑HER2 BLA, submitted b
OS Therapies shares are trading lower. The company requested a Type B Meeting to follow up on FDA guidance for its OST‑HER2 BLA, submitted biomarker data to the BEST program, added a synthetic control arm, and sought Rol
EARNINGS | Jun 30, 2026, 05:58 PM UTC
H
OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall
OS Therapies, Inc. (NYSE: OSTX ) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provided regulatory update on the Company's interactions with the U.S. Foo
EARNINGS | Jun 30, 2026, 11:45 AM UTC
L
OSTX Publishes Clinical Trial Data
OSTX OS Animal Health announces peer-reviewed publication of clinical trial data for OST-HER2 plus palliative radiation as frontline treatment in canine osteosarcoma
EQUITY | Jun 26, 2026, 11:47 AM UTC